[Skip to Content]
[Skip to Content Landing]
Views 680
Citations 0
Research Letter
July 2016

Evaluation of Effectiveness of Mixed Rotavirus Vaccine Course for Rotavirus Gastroenteritis

Author Affiliations
  • 1Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
JAMA Pediatr. 2016;170(7):708-710. doi:10.1001/jamapediatrics.2016.0014

Two rotavirus vaccines—RotaTeq (RV5; Merck and Company), a 3-dose series, and Rotarix (RV1; GlaxoSmithKline Biologicals), a 2-dose series—are licensed for use in US children. The US Advisory Committee for Immunization Practices (ACIP) recommends that a rotavirus vaccine series be completed with the same product whenever possible but allows for administering mixed vaccine types if a previous dose type is not available or is unknown.1 In such situations, the ACIP recommends, “If any dose in the series was RV5 or the vaccine product is unknown for any dose in the series, a total of 3 doses of rotavirus vaccine should be administered.”1 However, the effectiveness of a mixed rotavirus vaccine series remains unclear.

First Page Preview View Large
First page PDF preview
First page PDF preview